胰腺癌诊疗指南 (2022年版)

2022-04-11 国家癌症中心 卫健委官网

近年来,胰腺癌的发病率在国内外均呈明显的上升趋势。2021年统计数据显示,在美国所有恶性肿瘤中,胰腺癌新发病例男性位列第10位,女性第9位,占恶性肿瘤相关死亡率的第4位。中国国家癌症中心2021年统计

中文标题:

胰腺癌诊疗指南 (2022年版)

发布机构:

国家癌症中心

发布日期:

2022-04-11

简要介绍:

近年来,胰腺癌的发病率在国内外均呈明显的上升趋势。2021年统计数据显示,在美国所有恶性肿瘤中,胰腺癌新发病例男性位列第10位,女性第9位,占恶性肿瘤相关死亡率的第4位。中国国家癌症中心2021年统计数据显示,胰腺癌位居我国男性恶性肿瘤发病率的第7位,女性第11位,占恶性肿瘤相关死亡率的第6位。(本文所述胰腺癌均特指胰腺导管腺癌)

相关资料下载:
[AttachmentFileName(sort=1, fileName=胰腺癌诊疗指南 (2022年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=6f8241c002a10886, title=胰腺癌诊疗指南 (2022年版), enTitle=, guiderFrom=卫健委官网, authorId=0, author=, summary=近年来,胰腺癌的发病率在国内外均呈明显的上升趋势。2021年统计数据显示,在美国所有恶性肿瘤中,胰腺癌新发病例男性位列第10位,女性第9位,占恶性肿瘤相关死亡率的第4位。中国国家癌症中心2021年统计, cover=https://img.medsci.cn/20220414/1649876534829_5579292.png, journalId=0, articlesId=null, associationId=1931, associationName=国家癌症中心, associationIntro=国家癌症中心, copyright=0, guiderPublishedTime=Mon Apr 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #000000;">近年来,胰腺癌的发病率在国内外均呈明显的上升趋势。</span><span style="color: #000000;">2021</span><span style="color: #000000;">年统计数据显示,在美国所有恶性肿瘤中,胰腺癌新发病例男性位列第</span><span style="color: #000000;">10</span><span style="color: #000000;">位,女性第</span><span style="color: #000000;">9</span><span style="color: #000000;">位,占恶性肿瘤相关死亡率的第</span><span style="color: #000000;">4</span><span style="color: #000000;">位。中国国家癌症中心</span><span style="color: #000000;">2021</span><span style="color: #000000;">年统计数据显示,胰腺癌位居我国男性恶性肿瘤发病率的第</span><span style="color: #000000;">7</span><span style="color: #000000;">位,女性第</span><span style="color: #000000;">11</span><span style="color: #000000;">位,占恶性肿瘤相关死亡率的第</span><span style="color: #000000;">6</span><span style="color: #000000;">位。(本文所述胰腺癌均特指胰腺导管腺癌)</span></p>, tagList=[TagDto(tagId=439, tagName=消化道肿瘤), TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7144, appHits=358, showAppHits=0, pcHits=1605, showPcHits=6786, likes=1, shares=78, comments=5, approvalStatus=1, publishedTime=Thu Apr 14 15:26:00 CST 2022, publishedTimeString=2022-04-11, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Apr 14 03:03:32 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:05:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=胰腺癌诊疗指南 (2022年版).pdf)])
胰腺癌诊疗指南 (2022年版).pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2122298, encodeId=34c321222986c, content=医疗非常好,对学习有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba8610158, createdName=ms4000000015168880, createdTime=Tue Mar 28 19:00:41 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1214810, encodeId=3ee7121481078, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:16:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212003, encodeId=ac81121200320, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Sun Apr 17 21:35:41 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2023-03-28 ms4000000015168880 来自四川省

    医疗非常好,对学习有帮助

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2122298, encodeId=34c321222986c, content=医疗非常好,对学习有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba8610158, createdName=ms4000000015168880, createdTime=Tue Mar 28 19:00:41 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1214810, encodeId=3ee7121481078, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:16:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212003, encodeId=ac81121200320, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Sun Apr 17 21:35:41 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2122298, encodeId=34c321222986c, content=医疗非常好,对学习有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ba8610158, createdName=ms4000000015168880, createdTime=Tue Mar 28 19:00:41 CST 2023, time=2023-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1214810, encodeId=3ee7121481078, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:16:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212003, encodeId=ac81121200320, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Sun Apr 17 21:35:41 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-17 jing0309

    感谢分享

    0